Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

19.33USD
17 May 2019
Change (% chg)

$-0.46 (-2.32%)
Prev Close
$19.79
Open
$19.61
Day's High
$19.81
Day's Low
$19.27
Volume
871,742
Avg. Vol
1,066,610
52-wk High
$25.31
52-wk Low
$13.43

Latest Key Developments (Source: Significant Developments)

Exelixis And Iconic Therapeutics Enter Into Exclusive Option And License Agreement For Novel Antibody-Drug Conjugate Program
Thursday, 16 May 2019 

May 16 (Reuters) - Exelixis Inc ::EXELIXIS AND ICONIC THERAPEUTICS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR NOVEL ANTIBODY-DRUG CONJUGATE PROGRAM.EXELIXIS INC - ICON-2 PROGRAM TARGETS TISSUE FACTOR (TF) WITH POTENTIAL BROAD IMPACT IN ONCOLOGY.EXELIXIS INC - EXELIXIS WILL MAKE UPFRONT PAYMENT AND CONTRIBUTE RESEARCH FUNDING FOR OPTION TO IN-LICENSE AT INVESTIGATIONAL NEW DRUG (IND) FILING.EXELIXIS INC - WILL GAIN AN OPTION TO LICENSE ICON-2, ICONIC'S LEAD ONCOLOGY ADC PROGRAM, IN EXCHANGE FOR AN UPFRONT OPTION PAYMENT OF $7.5 MILLION.  Full Article

Exelixis Says CEO Michael M. Morrissey's 2018 Total Compensation Was $8 Mln Vs $9.4 Mln In 2017
Thursday, 11 Apr 2019 

April 11 (Reuters) - Exelixis Inc ::EXELIXIS INC SAYS CEO MICHAEL M. MORRISSEY'S 2018 TOTAL COMPENSATION WAS $8 MILLION VERSUS $9.4 MILLION IN 2017 – SEC FILING.EXELIXIS INC - CEO TO MEDIAN EMPLOYEE PAY RATIO FOR FISCAL 2018 WAS 32 TO 1.  Full Article

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial Of Cabozantinib
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN INITIATE PHASE 3 PIVOTAL TRIAL (COSMIC-312) OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN PREVIOUSLY UNTREATED ADVANCED HEPATOCELLULAR CARCINOMA.  Full Article

Exelixis' Partner Ipsen Receives European Commission Approval Of Cabometyx Tablets
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS PREVIOUSLY TREATED WITH SORAFENIB.UNDER TERMS OF COLLABORATION AGREEMENT WITH IPSEN, EXELIXIS WILL RECEIVE A MILESTONE PAYMENT OF $40 MILLION FOR EUROPEAN COMMISSION APPROVAL.PAYMENT WILL BE PAID BY IPSEN WITHIN NEXT 70 DAYS.  Full Article

Exelixis Announces Q3 Earnings Per Share $0.41
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 EARNINGS PER SHARE $0.41.Q3 REVENUE $225.4 MILLION VERSUS $152.5 MILLION.Q3 REVENUE VIEW $172.6 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES 2018 TOTAL COSTS AND OPERATING EXPENSES BETWEEN $410 MILLION AND $420 MILLION.  Full Article

Exelixis' Partner Ipsen Announces Health Canada's Approval Of Cabometyx Tablets
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN ANNOUNCES HEALTH CANADA’S APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - UNDER TERMS OF COLLABORATION AGREEMENT WITH IPSEN, CO WILL RECEIVE A MILESTONE PAYMENT OF $5 MILLION FOR HEALTH CANADA APPROVAL.EXELIXIS INC - PAYMENT WILL BE MADE BY IPSEN WITHIN NEXT 70 DAYS.EXELIXIS - UNDER TERMS OF AGREEMENT WITH IPSEN, CO WILL RECEIVE A MILESTONE PAYMENT OF $5 MILLION FOR HEALTH CANADA APPROVAL.  Full Article

Exelixis Says Ipsen received validation of the application for variation to the Cabometyx
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.‍FILING IS BASED ON RESULTS OF GLOBAL PIVOTAL PHASE 3 CELESTIAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS)​.‍CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS COMPARED WITH PLACEBO​.  Full Article

Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Exelixis Inc ::CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​.‍FILING TRIGGERS $20 MILLION MILESTONE PAYMENT TO EXELIXIS​.  Full Article

Exelixis Posts Q4 Earnings Per Share $0.12
Tuesday, 27 Feb 2018 

Feb 26 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.12.Q4 REVENUE $120.1 MILLION VERSUS $77.6 MILLION.  Full Article

Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Wednesday, 14 Feb 2018 

Feb 13 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA.EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​.EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​.  Full Article